{"id":"NCT03537651","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation","officialTitle":"A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older, Homozygous or Heterozygous for the F508del-CFTR Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-25","primaryCompletion":"2020-10-28","completion":"2023-09-29","firstPosted":"2018-05-25","resultsPosted":"2021-11-26","lastUpdate":"2024-04-19"},"enrollment":130,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"TEZ/IVA","otherNames":["VX-661/VX-770","tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]}],"arms":[{"label":"TEZ/IVA","type":"EXPERIMENTAL"}],"summary":"This study evaluates the long-term safety and tolerability of tezacaftor in combination with ivacaftor (TEZ/IVA) in participants with cystic fibrosis (CF) aged 6 years and older, homozygous or heterozygous for the F508del mutation.","primaryOutcome":{"measure":"Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"Day 1 up to Week 100","effectByArm":[{"arm":"Part A: TEZ/IVA","deltaMin":129,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":55,"countries":["United States","Australia","Belgium","Canada","Denmark","France","Germany","Ireland","Poland","Switzerland","United Kingdom"]},"refs":{"pmids":["37983082","35190292","33331662"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":130},"commonTop":["Cough","Infective pulmonary exacerbation of cystic fibrosis","Upper respiratory tract infection","Nasopharyngitis","Oropharyngeal pain"]}}